Brief: Theranexus Authorized To Start Phase IB Clinical Trial With THN201

Thx Pharma SA

26/09/2018 06:36

Sept 26 (Reuters) - THERANEXUS SA  ALTHX.PA :
    * THERANEXUS OBTAINS THE AUTHORIZATION TO START A PHASE IB
CLINICAL TRIAL WITH ITS DRUG CANDIDATE THN201 IN NEUROCOGNITIVE
DISORDERS DUE TO ALZHEIMER'S DISEASE
    * STUDY AIMED AT DEMONSTRATING CLINICAL SUPERIORITY OF
THN201 OVER
A STANDARD OF CARE TREATMENT FOR THIS SEVERELY DEBILITATING
SYMPTOM
    * RESULTS OF THIS STUDY WILL BE AVAILABLE AT END OF 2019 -
CEO

Source text for Eikon:  ID:nACT55156 
Further company coverage:  ALTHX.PA 

 (Gdynia Newsroom:)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))